v3.26.1
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Common Shares
Pre-funded warrants
Additional paid-in capital
Accumulated deficit
Total
Beginning balance at Dec. 31, 2024 $ 288,048 $ 53,076 $ 39,568 $ (367,545) $ 13,147
Beginning Balance (in shares) at Dec. 31, 2024 53,353,984        
Beginning Balance, warrants (in shares) at Dec. 31, 2024   12,910,590      
Transactions during the period          
Net loss       (33,727) (33,727)
Exercise of stock options $ 75   (39)   36
Exercise of stock options (in shares) 29,988        
Share-based compensation     2,659   2,659
Employee stock purchase plan purchases $ 140       140
Employee stock purchase plan purchases (in shares) 110,289        
Ending balance at Jun. 30, 2025 $ 288,263 $ 53,076 42,188 (401,272) (17,745)
Ending Balance, warrants (in shares) at Jun. 30, 2025   12,910,590      
Ending Balance (in shares) at Jun. 30, 2025 53,494,261        
Beginning balance at Mar. 31, 2025 $ 288,188 $ 53,076 40,919 (388,306) (6,123)
Beginning Balance (in shares) at Mar. 31, 2025 53,464,273        
Beginning Balance, warrants (in shares) at Mar. 31, 2025   12,910,590      
Transactions during the period          
Net loss       (12,966) (12,966)
Exercise of stock options $ 75   (39)   36
Exercise of stock options (in shares) 29,988        
Share-based compensation     1,308   1,308
Ending balance at Jun. 30, 2025 $ 288,263 $ 53,076 42,188 (401,272) (17,745)
Ending Balance, warrants (in shares) at Jun. 30, 2025   12,910,590      
Ending Balance (in shares) at Jun. 30, 2025 53,494,261        
Beginning balance at Dec. 31, 2025 $ 352,619 $ 55,649 64,104 (430,603) $ 41,769
Beginning Balance (in shares) at Dec. 31, 2025 106,236,344       106,236,344
Beginning Balance, warrants (in shares) at Dec. 31, 2025   16,412,925     16,412,925
Transactions during the period          
Net loss       (54,680) $ (54,680)
Exercise of stock options $ 53   (25)   28
Exercise of stock options (in shares) 24,921        
Exercise of Series A common stock warrants, net of issuance costs $ 20,759   (3,352)   17,407
Exercise of Series A common stock warrants, net of issuance costs (in shares) 12,345,308        
Share-based compensation     2,620   2,620
Issuance of common shares, vesting of restricted stock units $ 480   (480)    
Issuance of common shares, vesting of restricted stock units (in shares) 237,677        
Issuance of common shares, net of issuance costs $ 10,890       10,890
Issuance of common shares, net of issuance costs (in shares) 5,526,590        
Employee stock purchase plan purchases $ 184       184
Employee stock purchase plan purchases (in shares) 127,140        
Ending balance at Jun. 30, 2026 $ 384,985 $ 55,649 62,867 (485,283) $ 18,218
Ending Balance, warrants (in shares) at Jun. 30, 2026   16,412,925     16,412,925
Ending Balance (in shares) at Jun. 30, 2026 124,497,980       124,497,980
Beginning balance at Mar. 31, 2026 $ 373,702 $ 55,649 63,367 (456,669) $ 36,049
Beginning Balance (in shares) at Mar. 31, 2026 117,794,417        
Beginning Balance, warrants (in shares) at Mar. 31, 2026   16,412,925      
Transactions during the period          
Net loss       (28,614) (28,614)
Exercise of stock options $ 53   (25)   28
Exercise of stock options (in shares) 24,921        
Exercise of Series A common stock warrants, net of issuance costs $ 11,230   (1,813)   9,417
Exercise of Series A common stock warrants, net of issuance costs (in shares) 6,678,642        
Share-based compensation     1,338   1,338
Ending balance at Jun. 30, 2026 $ 384,985 $ 55,649 $ 62,867 $ (485,283) $ 18,218
Ending Balance, warrants (in shares) at Jun. 30, 2026   16,412,925     16,412,925
Ending Balance (in shares) at Jun. 30, 2026 124,497,980       124,497,980